Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.58 |
| ▸ | PRKACB | P22694 | 1/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | NMBR | P28336 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593284 | 0.96 | NPBWR1 (0.58) | GHSRPRKACBNPBWR1IL23R | |
| SCHEMBL29485122 | 0.96 | GHSR (0.54) | GHSRPRKACBMC4R | |
| SCHEMBL31593260 | 0.95 | NPBWR1 (0.57) | GHSRPRKACBNPBWR1IL23R | |
| SCHEMBL30883343 | 0.93 | IL23R (0.55) | GHSRPRKACBIL23R | |
| SCHEMBL31593302 | 0.92 | NPBWR1 (0.54) | GHSRPRKACBNPBWR1MC4RIL23R | |
| SCHEMBL31593263 | 0.92 | NPBWR1 (0.62) | GHSRPRKACBNPBWR1IL23R | |
| SCHEMBL31593359 | 0.92 | GHSR (0.56) | GHSRPRKACBNPBWR1NMBR | |
| SCHEMBL29483773 | 0.92 | GHSR (0.56) | GHSRPRKACBNPBWR1NMBR | |
| SCHEMBL29609515 | 0.92 | GHSR (0.56) | GHSRPRKACBNPBWR1NMBR | |
| SCHEMBL29609768 | 0.92 | GHSR (0.56) | GHSRPRKACBNPBWR1NMBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | GHSR 2961/4885PRKACB 4413/4885NPBWR1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.